ISLET TRANSPLANTATION
Clinical Islet Transplantation Consortium (CIT) : The goal of the CIT05 studies is to determine the proportion of subjects who are insulin independent at 75 ± 5 days following one islet cell infusion among subjects treated with an experimental islet transplant immunosuppression regimen which includes rituximab and excludes tacrolimus.
Study Names:Strategies to Improve Long Term Islet Graft Survival, B-Lymphocyte Immunotherapy in Islet Transplantation, Efficacy of Islet after Kidney Transplantation , Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes, Islet Transplantation in Type 1 Diabetes with LEA29Y Maintenance Therapy, Islet Transplantation in Type 1 Diabetes
Back to Clinical Studies Recruiting Type 1 Diabetes Patients and Family Members